Legal & General Group’s Protalix BioTherapeutics PLX Stock Holding History

Legal & General Group’s Portfolio PLX Stock Details PLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$13.7K	Sell	6,333 -868	-12%	-$2.15K	﹤0.01%	3107
2025 Q4	$13K	Sell	7,201 -556	-7%	-$1.14K	﹤0.01%	3177
2025 Q3	$17.2K	Hold	7,757	–	–	﹤0.01%	3102
2025 Q2	$11.5K	Buy	+7,757	New	+$15.9K	﹤0.01%	3232
2024 Q2	–	Sell	-5,359	Closed	-$6.75K	–	3487
2024 Q1	$6.75K	Hold	5,359	–	–	﹤0.01%	3263
2023 Q4	$9.54K	Hold	5,359	–	–	﹤0.01%	3244
2023 Q3	$8.9K	Hold	5,359	–	–	﹤0.01%	3290
2023 Q2	$10.7K	Buy	+5,359	New	+$12.8K	﹤0.01%	3306

Other funds holding PLX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

MCO

MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SWP

Stratos Wealth Partners Beachwood, Ohio $8.8B AUM 21.82% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

PFS

Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Legal & General Group's PLX Position: Q1 2026 in Review

Legal & General Group reduced its Protalix BioTherapeutics (PLX) stake by 12% in Q1 2026, selling an estimated $2.15K and leaving 6,333 shares worth $13.7K. The position accounts for ﹤0.01% of the portfolio, ranked #3107.

Legal & General Group first reported a position in PLX in Q2 2023 and has held it in 8 quarters since. The position peaked at $17.2K in Q3 2025. 100 funds tracked by Wall St. Rank hold PLX as of Q1 2026.

Legal & General Group held 6,333 shares of Protalix BioTherapeutics worth $13.7K as of Q1 2026.
Legal & General Group sold 868 Protalix BioTherapeutics shares in Q1 2026, an estimated $2.15K.
Protalix BioTherapeutics made up ﹤0.01% of Legal & General Group's portfolio in Q1 2026, its #3107 holding.
Legal & General Group first reported a position in Protalix BioTherapeutics in Q2 2023 and has held it in 8 quarters since.
Legal & General Group's Protalix BioTherapeutics position peaked at $17.2K in Q3 2025.
100 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q1 2026.

Based on Legal & General Group's 13F filing for Q1 2026, filed 8 May 2026.